Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMMP Prima BioMed	$1.64 +0.6%	$1.78	$1.32 ▼ $2.72	$238.04M	1.71	158,131 shs	73,418 shs
SCYX SCYNEXIS	$0.76	$0.81	$0.66 ▼ $2.28	$29.66M	1.57	164,989 shs	153,839 shs
VCNX Vaccinex	$0.87 -11.1%	$0.82	$0.25 ▼ $8.90	$2.76M	1.1	55,799 shs	427 shs
XERS Xeris Biopharma	$5.26 -0.6%	$4.79	$2.10 ▼ $6.07	$827.27M	0.66	2.06 million shs	2.06 million shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMMP Prima BioMed	+0.61%	-2.96%	-4.09%	+6.49%	-19.21%
SCYX SCYNEXIS	0.00%	+9.35%	-3.18%	-15.96%	-65.92%
VCNX Vaccinex	-11.12%	-2.25%	+22.54%	+17.57%	-85.43%
XERS Xeris Biopharma	-0.57%	-1.50%	+19.55%	+27.98%	+104.67%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IMMP Prima BioMed	1.501 of 5 stars	3.5	1.0	0.0	3.3	0.0	0.0
SCYX SCYNEXIS	1.0695 of 5 stars	0.0	3.0	0.0	3.8	0.8	0.6
VCNX Vaccinex	0.8235 of 5 stars	0.0	5.0	0.0	0.6	2.5	0.0
XERS Xeris Biopharma	3.9536 of 5 stars	2.4	3.0	4.2	3.3	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IMMP Prima BioMed	3.00	Buy	$7.00	326.83% Upside
SCYX SCYNEXIS	0.00	N/A	N/A	N/A
VCNX Vaccinex	0.00	N/A	N/A	N/A
XERS Xeris Biopharma	2.83	Moderate Buy	$6.25	18.82% Upside

Current Analyst Ratings Breakdown

Latest IMMP, XERS, SCYX, and VCNX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
5/9/2025	XERS Xeris Biopharma	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$6.00 ➝ $7.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IMMP Prima BioMed	$5.14M	46.60	N/A	N/A	$1.05 per share	1.56
SCYX SCYNEXIS	$3.75M	7.91	N/A	N/A	$1.45 per share	0.52
VCNX Vaccinex	$388K	5.83	N/A	N/A	($2.59) per share	-0.34
XERS Xeris Biopharma	$203.07M	4.05	N/A	N/A	($0.20) per share	-26.30

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IMMP Prima BioMed	-$28.01M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/29/2025 (Estimated)
SCYX SCYNEXIS	-$21.29M	-$0.56	N/A	15.20	N/A	-1,030.04%	-53.47%	-32.86%	8/6/2025 (Estimated)
VCNX Vaccinex	-$20.25M	-$48.27	N/A	∞	N/A	N/A	N/A	-383.58%	8/12/2025 (Estimated)
XERS Xeris Biopharma	-$54.84M	-$0.30	N/A	N/A	N/A	-20.25%	N/A	-12.07%	8/6/2025 (Estimated)

Latest IMMP, XERS, SCYX, and VCNX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/15/2025	Q1 2025	SCYX SCYNEXIS	-$0.23	-$0.17	+$0.06	-$0.11	$0.14 million	$0.26 million
5/8/2025	Q1 2025	XERS Xeris Biopharma	-$0.07	-$0.06	+$0.01	-$0.06	$57.61 million	$57.80 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IMMP Prima BioMed	N/A	N/A	N/A	N/A	N/A
SCYX SCYNEXIS	N/A	N/A	N/A	N/A	N/A
VCNX Vaccinex	N/A	N/A	N/A	N/A	N/A
XERS Xeris Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IMMP Prima BioMed	N/A	18.86	N/A
SCYX SCYNEXIS	N/A	5.83	5.83
VCNX Vaccinex	N/A	0.77	0.77
XERS Xeris Biopharma	N/A	1.72	1.17

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IMMP Prima BioMed	2.32%
SCYX SCYNEXIS	54.37%
VCNX Vaccinex	50.11%
XERS Xeris Biopharma	42.75%

Insider Ownership

Company	Insider Ownership
IMMP Prima BioMed	3.07%
SCYX SCYNEXIS	4.86%
VCNX Vaccinex	51.50%
XERS Xeris Biopharma	6.47%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IMMP Prima BioMed	2,021	146.04 million	141.56 million	Optionable
SCYX SCYNEXIS	60	39.02 million	37.12 million	Optionable
VCNX Vaccinex	40	2.60 million	1.26 million	No Data
XERS Xeris Biopharma	290	156.38 million	146.27 million	Optionable

IMMP, XERS, SCYX, and VCNX Headlines

Recent News About These Companies

CenterBook Partners LP Cuts Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

July 16 at 10:32 AM | marketbeat.com

Brown Advisory Inc. Has $630,000 Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

July 15 at 4:13 AM | marketbeat.com

Xeris Biopharma Holdings, Inc. (XERS) - Yahoo Finance

July 10, 2025 | finance.yahoo.com

Xeris Biopharma (NASDAQ:XERS) Trading 7.4% Higher - Time to Buy?

July 9, 2025 | marketbeat.com

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Consensus Rating of "Moderate Buy" from Analysts

June 28, 2025 | marketbeat.com

Xeris Biopharma: Great Numbers, Great Technologies, And Suitable For Long-Term Investing

June 18, 2025 | seekingalpha.com

Xeris Biopharma (NASDAQ:XERS) Trading Up 8.4% on Insider Buying Activity

June 17, 2025 | marketbeat.com

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Insider Kevin Mcculloch Buys 25,000 Shares

June 17, 2025 | insidertrades.com

Xeris Biopharma touts ambitious growth plan, promising hypothyroidism drug

June 4, 2025 | chicagobusiness.comC

Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day

June 3, 2025 | finance.yahoo.com

Xeris Announces Details for Analyst & Investor Day

May 20, 2025 | businesswire.com

Xeris Biopharma Holdings, Inc. (XERS): Among the Unstoppable Growth Stocks to Invest in Now

May 12, 2025 | msn.com

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q1 2025 Earnings Call Transcript

May 10, 2025 | insidermonkey.com

Xeris Biopharma Holdings Inc (XERS) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ...

May 9, 2025 | finance.yahoo.com

Xeris Biopharma Holdings, Inc. (XERS) Q1 2025 Earnings Call Transcript

May 8, 2025 | seekingalpha.com

Xeris Biopharma (XERS) Reports Q1 Loss, Tops Revenue Estimates

May 8, 2025 | zacks.com

Xeris Biopharma Reports Record First Quarter 2025 Financial Results

May 8, 2025 | businesswire.com

4XERS : Earnings Outlook For Xeris Biopharma Holdings

May 7, 2025 | benzinga.com

Xeris Biopharma Holdings: Looking For More Growth In Q1 Earnings

May 7, 2025 | seekingalpha.com

Xeris Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025

May 2, 2025 | seekingalpha.com

Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Shift From Loss To Profit

April 26, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMMP, XERS, SCYX, and VCNX Company Descriptions

Prima BioMed NASDAQ:IMMP

$1.64 +0.01 (+0.61%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$1.66 +0.03 (+1.52%)

As of 06:18 AM Eastern

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

SCYNEXIS NASDAQ:SCYX

$0.76 0.00 (0.00%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$0.76 +0.00 (+0.39%)

As of 07:00 AM Eastern

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

Vaccinex NASDAQ:VCNX

$0.87 -0.11 (-11.12%)

As of 07/16/2025 01:47 PM Eastern

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 study for treatment of Alzheimer's disease and has completed phase 2 study for treatment of Huntington's disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer, Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 study with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab completed phase 2 study for melanoma, and trastuzumab and DC vaccine in phase 2 study for breast cancer. The company has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; The Children's Hospital of Philadelphia; Emory University; Huntington Study Group; H. Lee Moffitt Cancer Center and Research Institute, Inc; Catalent Pharma Solutions, LLC; Surface Oncology, Inc.; and Pharmaceutical and Biotech Co. The company was incorporated in 2001 and is headquartered in Rochester, New York.

Xeris Biopharma NASDAQ:XERS

$5.26 -0.03 (-0.57%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$5.38 +0.12 (+2.19%)

As of 07:17 AM Eastern

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time